Review article · 2024 · Open access
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
Signal Transduction and Targeted Therapy, 9(1), 211 · Published 23 August 2024 · DOI 10.1038/s41392-024-01911-3
In brief
“Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies” is a 2024 review article by Jifa Zhang and 5 co-authors, published in Signal Transduction and Targeted Therapy. OpenAlex counts 1,384 citations as of 15 November 2026, which puts it in the top 1% of works published in 2024 by citations. It is open access under a CC BY licence: the full text is free to read at Signal Transduction and Targeted Therapy.
- Citations
- 1,384
- Most cited in
- 2026 (714)
- Field-weighted impact
- 58.49
- References
- 650
- Authors
- 6
Abstract
Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant and escalating global challenges. Its etiology is intricate and diverse, stemming from a combination of factors such as aging, genetics, and environment. Our current understanding of AD pathologies involves various hypotheses, such as the cholinergic, amyloid, tau protein, inflammatory, oxidative stress, metal ion, glutamate excitotoxicity, microbiota-gut-brain axis, and abnormal autophagy. Nonetheless, unraveling the interplay among these pathological aspects and pinpointing the primary initiators of AD require further elucidation and validation. In the past decades, most clinical drugs have been discontinued due to limited effectiveness or adverse effects. Presently, available drugs primarily offer symptomatic relief and often accompanied by undesirable side effects. However, recent approvals of aducanumab (1) and lecanemab (2) by the Food and Drug Administration (FDA) present the potential in disrease-modifying effects. Nevertheless, the long-term efficacy and safety of these drugs need further validation. Consequently, the quest for safer and more effective AD drugs persists as a formidable and pressing task. This review discusses the current understanding of AD pathogenesis, advances in diagnostic biomarkers, the latest updates of clinical trials, and emerging technologies for AD drug development. We highlight recent progress in the discovery of selective inhibitors, dual-target inhibitors, allosteric modulators, covalent inhibitors, proteolysis-targeting chimeras (PROTACs), and protein-protein interaction (PPI) modulators. Our goal is to provide insights into the prospective development and clinical application of novel AD drugs.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024). Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduction and Targeted Therapy, 9(1), 211. https://doi.org/10.1038/s41392-024-01911-3
MLA 9
Zhang, Jifa, et al. “Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies.” Signal Transduction and Targeted Therapy, vol. 9, no. 1, 2024, p. 211. https://doi.org/10.1038/s41392-024-01911-3.
Chicago
Zhang, Jifa, Yinglu Zhang, Jiaxing Wang, Yilin Xia, Jiaxian Zhang, and Lei Chen. 2024. “Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies.” Signal Transduction and Targeted Therapy 9 (1): 211. https://doi.org/10.1038/s41392-024-01911-3.
Harvard
Zhang, J. et al. (2024) ‘Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies’, Signal Transduction and Targeted Therapy, 9(1), p. 211. doi:10.1038/s41392-024-01911-3.
IEEE
J. Zhang, Y. Zhang, J. Wang, Y. Xia, J. Zhang, and L. Chen, “Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies,” Signal Transduction and Targeted Therapy, vol. 9, no. 1, p. 211, 2024, doi: 10.1038/s41392-024-01911-3.
BibTeX
@article{zhang2024recent,
title = {{Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies}},
author = {Zhang, Jifa and Zhang, Yinglu and Wang, Jiaxing and Xia, Yilin and Zhang, Jiaxian and Chen, Lei},
journal = {Signal Transduction and Targeted Therapy},
year = {2024},
volume = {9},
number = {1},
pages = {211},
doi = {10.1038/s41392-024-01911-3},
url = {https://doi.org/10.1038/s41392-024-01911-3}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 33 | |
| 2025 | 637 | |
| 2026 | 714 |
Its field-weighted citation impact is 58.49: it has been cited 58.49 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- Alzheimer's disease pathogenesis
- amyloid hypothesis
- tau protein
- cholinergic hypothesis
- neuroinflammation
- oxidative stress
- microbiota-gut-brain axis
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024). Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduction and Targeted Therapy, 9(1), 211. https://doi.org/10.1038/s41392-024-01911-3
How many times has this paper been cited?
1,384 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Signal Transduction and Targeted Therapy.
Who wrote this paper?
Jifa Zhang, Yinglu Zhang, Jiaxing Wang, Yilin Xia, Jiaxian Zhang, Lei Chen.
What is the DOI of this paper?
10.1038/s41392-024-01911-3. The permanent link is https://doi.org/10.1038/s41392-024-01911-3.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.